Cobalt-catalyzed cross-electrophile couplings: from electrosynthesis to conventional chemistry
Comptes Rendus. Chimie · 16.12.2025 · 28 (G1) · 887-900
DOI: 10.5802/crchim.420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Comptes Rendus. Chimie, online erschienen am 16.12.2025. Verfasst von Corinne Gosmini. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben.
Abstract (Originalsprache)
Cobalt-catalyzed reductive cross-couplings, also known as cross-electrophile couplings (XECs), have emerged as a valuable and sustainable alternative to classical cross-coupling strategies. Unlike traditional methods relying on preformed organometallic reagents, cobalt catalysis enables the direct coupling of two electrophiles, offering broad functional group tolerance, access to diverse C(sp 2 )–C(sp 2 ), C(sp 2 )–C(sp 3 ), and C(sp 3 )–C(sp 3 ) bonds, and compatibility with mild conditions. Building on early electrochemical studies, significant progress has been made in both electrosynthesis (eXEC) and conventional approaches (XEC), highlighting cobalt’s cost-effectiveness, ecological advantages, and complementary reactivity compared to nickel. This account summarizes the development of cobalt-catalyzed reductive cross-couplings, from pioneering contributions to recent advances, with emphasis on mechanistic aspects and substrate scope.
Zitieren
APA
Gosmini, C. (2025). Cobalt-catalyzed cross-electrophile couplings: from electrosynthesis to conventional chemistry. Comptes Rendus. Chimie, 28(G1), 887-900. https://doi.org/10.5802/crchim.420
Vancouver
Gosmini C. Cobalt-catalyzed cross-electrophile couplings: from electrosynthesis to conventional chemistry. Comptes Rendus. Chimie. 2025;28(G1):887-900. doi:10.5802/crchim.420
BibTeX
@article{Gosmini2025,
author = {Gosmini, Corinne},
title = {Cobalt-catalyzed cross-electrophile couplings: from electrosynthesis to conventional chemistry},
journal = {Comptes Rendus. Chimie},
year = {2025},
volume = {28},
number = {G1},
pages = {887--900},
doi = {10.5802/crchim.420}
}
EUVIMED